Shares of OptimizeRx moved lower after Seeking Alpha contributor “Western Edge” questioned the company’s financials. OptimizeRx’s CEO and related parties “are tainted with what I see as a history of ethical lapses under their watch, and have been cited for producing inaccurate financials,” the contributor writes. Further, the company has a “lengthy history of excessive auditor turnover, a reliance on sanctioned auditing firms, and chronic auditor concerns over the reliability of their financial statements,” says Western Edge. Shares of OptimizeRx are down 13%, or $2.89, to $18.95.
previous post